معرفی
Henrik Gregersen is a Clinical Professor at Aalborg University Hospital’s Department of Haematology within the Faculty of Medicine at Aalborg University. His research focuses on hematology, particularly multiple myeloma, monoclonal gammopathy, and the impact of socioeconomic factors on patient outcomes. He is actively involved in clinical trials, such as those evaluating carfilzomib and stem-cell transplantation efficacy, and has contributed to over 86 publications since 1998.
Dr. Gregersen’s work spans clinical pharmacology and oncology, with recent studies analyzing chemotherapy-induced neuropathy and immunoglobulin measurement accuracy. He serves on the board of the Danish Hematological Society and has presented at international conferences like the American Society of Hematology Annual Meeting. His research has garnered media attention, including coverage on carfilzomib’s role in extending survival for multiple myeloma patients.
Collaboration highlights include the Nordic Myeloma Study Group, emphasizing his role in advancing hematological research and patient care. While no explicit awards are listed, his extensive publication record and leadership roles underscore his contributions to the field.
